There’s been a rapid shift towards decentralization in clinical trials & it’s clear why.
The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient.
Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.
Yet, it’s important to note that there’s a significant learning curve for sponsors as these new methods graduate from early-phase into larger pivotal trials that must prove efficacy.
There are pitfalls to avoid & key elements to keep front & center. Most trials won’t be fully virtual, but all trials will be more virtual.